Free Trial
NASDAQ:IBB

iShares Biotechnology ETF (IBB) Price, Holdings, & News

iShares Biotechnology ETF logo
$203.34 +0.24 (+0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$203.14 -0.20 (-0.10%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iShares Biotechnology ETF (NASDAQ:IBB)

Advanced

Key Stats

Today's Range
$201.12
▼
$205.81
50-Day Range
$185.91
▼
$216.96
52-Week Range
$149.09
▼
$217.12
Volume
1.48 million shs
Average Volume
1.61 million shs
Market Capitalization
$10.34 billion
Assets Under Management
$10.40 billion
Dividend Yield
0.17%
Net Expense Ratio
0.44%
Aggregate Rating
Moderate Buy

ETF Overview

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

iShares Biotechnology ETF Expenses

TypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.44%0.55%0.57%0.54%0.53%
Other Expenses0.00%0.52%0.53%0.38%0.54%
Total Expense0.44%0.76%0.75%0.69%0.73%
Fee Waiver0.00%-0.85%-0.67%-0.41%-0.68%
Net Expense0.44%0.58%0.63%0.61%0.60%
Receive IBB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IBB ETF News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Sector Update: Healthcare Stocks Lean Lower Premarket Monday
See More Headlines

IBB ETF - Frequently Asked Questions

iShares Biotechnology ETF's stock was trading at $168.77 at the start of the year. Since then, IBB shares have increased by 20.5% and is now trading at $203.34.

iShares Biotechnology ETF shares split on the morning of Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

iShares Biotechnology ETF's top institutional shareholders include Neville Rodie & Shaw Inc. (0.08%), Congress Asset Management Co. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%) and Elm3 Financial Group LLC.

Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Fund Details

Issuer
iShares
Fund Name
iShares Biotechnology ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:IBB
Inception Date
2/5/2001
Fund Manager
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
NYSE Biotechnology Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
248

Fund Statistics

Assets Under Management
$10.40 billion
Average Daily Volume
$1.62 million
Discount/Premium
-0.05%

Administrator, Advisor and Custodian

Administrator
J.P. Morgan Chase Bank, N.A.
Advisor
BlackRock Fund Advisors
Custodian
JPMorgan Chase Bank, N.A.
Distributor
BlackRock Investments, LLC
Transfer Agent
J.P. Morgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Latour Trading

Options

Optionable
Optionable
Options Volume
2,386
Put Options
1,478
Call Options
908
Short Interest
12,267,170 shs

Miscellaneous

Beta
0.70
Creation Unit
50,000
Creation Fee
$614.00
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Top 10 IBB Holdings

IBB Sector Exposure

IBB Industry Exposure


This page (NASDAQ:IBB) was last updated on 10/7/2026 by MarketBeat.com Staff.
From Our Partners